In doxorubicin-resistant human uterine sarcoma (MES-SA/Dx5), apigenin reduces intracellular glutathione (GSH) levels by inhibiting ATP-binding cassette subfamily B member 1 (ABCB1) [60], while in prostate cancer, it reverses doxorubicin resistance by down-regulating ABCB1 protein expression [61]. Here, ABCB1 is linked to prostate carcinoma.